Abstract
Background Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the population size benefiting from pneumococcal vaccines and the robustness of the immunogenic response to vaccination decline. This poses a conundrum for identifying the optimal age for vaccination. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning VE impact on optimal age for single-dose pneumococcal vaccination.
Methods Age- and vaccine-serotype-stratified IPD incidence from routine surveillance of adults ≥55 years old (y) in Brazil, England, Blantyre (Malawi), and South Africa, ≥4-years after infant-pneumococcal vaccine introduction and before 2020, was used to parameterise exponential growth models of increasing IPD risk with age. A piecewise-constant model estimated VE and waning VE from prior studies. All estimates were then combined in a cohort model to assess the vaccine preventable IPD burden of delivering 13-, 15-, 20-valent conjugate or 23-valent polysaccharide vaccines at various ages.
Findings In Brazil, Malawi, South Africa and England 51%, 51%, 54% and 39% of adults older than 55y were younger than 65y old. A smaller share of IPD was reported among adults <65y old in England (4,657 annual cases; 20% <65y) compared to Brazil (186; 45%), Malawi (4; 63%), or South Africa (134, 48%). PCV13- and PPV23-serotypes were estimated to cause 39% and 85% of IPD cases on average across settings. Vaccination at 55y in Brazil, Malawi, and South Africa, and at 70y in England had the greatest potential for IPD prevention with 38%, 31%, 27%, 8% of IPD preventable if using PCV13, 44%, 32%, 30%, 13% with PCV15, 65%, 69%, 53%, 37% with PCV20, and 30%, 29%, 20%, 14% with PPV23, respectively. Vaccination efficiency or cost effective use was optimal in 60-65y in Brazil, Malawi and South Africa, and in 80-85y in England.
Interpretation In low/middle-income countries, pneumococcal vaccines may prevent a substantial proportion of the residual IPD burden if administered earlier in adulthood than is typical in high-income countries.
Funding UK National Institute for Health and Care Research.
Evidence before this study A recent review conducted for the World Health Organisation (WHO) Scientific Advisory Group of Experts (SAGE) working group on pneumococcal vaccines reviewed the evidence on the efficacy, effectiveness and potential impact of pneumococcal vaccines in older adults. At the time, little evidence was identified to support recommendations for the age of pneumococcal vaccination in older adults, particularly in LMICs. We did an updated search of PubMed, Medline, Embase and Web of Science for studies on age targeting for pneumococcal vaccination in older adults published from Jan 1, 2003 to June 30, 2022, using the search terms “(optimal age targeting OR age targeting OR timeliness) AND (pneumococcal vaccination OR pneumococcal vaccines) AND (adults OR older adults OR elderly)”. We identified one study on the role of timeliness in the cost-effectiveness of older adult vaccination in Australia. This study explored the impact of the timeliness of pneumococcal conjugate vaccination (PCV) in older adults and found that more hospitalisations and deaths can be prevented if PCV13 was given to 70y old than as recommended at 65y. On the other hand, most low-income countries (LICs) and middle-income countries (MICs) do not have routine older adult pneumococcal vaccination programmes, despite often less indirect protection from childhood PCV programmes and high burden of vaccine preventable disease. The implications of differences in population demographics and risk for IPD compared to high income countries on the optimal age for pneumococcal vaccination in LICs/MICs are unknown.
Added value of this study This multicountry study uses data from long-standing older adult pneumococcal surveillance programmes at the national/sub-national level, to explore the optimal age-targeting for a single-dose pneumococcal vaccination against vaccine-serotype-IPD in older adults living without human immunodeficiency virus in LIC (Malawi), MICs (Brazil, South Africa), and HIC (England). We show that despite mature pneumococcal infant vaccination programmes there is a substantial burden of vaccine preventable pneumococcal disease remaining in the four countries considered. Vaccinating at 55y in the LICs/MICs was optimal whereas vaccinating at 70y prevented most IPD cases in England than vaccinating at other ages. While the number of older adults needed to vaccinate to prevent an IPD case may be higher for programmes vaccinating older individuals, vaccination efficiency or vaccine cost effective use was optimal in 60-65y in LICs/MICs, and in 80-85y in England.
Implications of all available evidence LICs/MICs with a mature infant immunisation programme for pneumococci and a remaining high burden of vaccine preventable pneumococcal disease in older adults may consider implementation of a vaccination programme for older adults, albeit at a younger age than typical in HICs. Affordability and cost-effectiveness of an adult vaccination programme as well as the indirect effects following potential changes to higher valency infant PCV vaccination programmes will also need to be considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A project grant from the National Institute for Health and Care Research (NIHR) Global Health Research Unit on Mucosal Pathogens (MPRU) is supported using UK aid from the UK Government (Grant 16/136/46). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The MLW Clinical Research Programme is supported by a Strategic Award from the Wellcome, UK. This research was funded in whole, or in part, by the Wellcome Trust [Grant number 208812/Z/17/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The funders had no role in study design, collection, analysis, data interpretation, writing of the report or in the decision to submit the paper for publication. The corresponding author and senior authors had full access to the study data, and together, had final responsibility for the decision to submit for publication
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Brazil Scientific Committee of the Instituto Adolfo Luiz gave ethical approval for this work Ethics committee/IRB of England UK Health Security Agency (UKHSA) gave ethical approval for this work Ethics committee/IRB of Malawi Kamuzu University of Health Sciences College of Medicine Research Ethics Committee gave ethical approval for this work Ethics committee/IRB of South Africa Health Research Ethics Committee (Human) University of Witwatersrand gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
An R script that was used to analyse the datasets and aggregated data are available in the GitHub repository.
https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines
